329-89-5
329-89-5
Chemical Structure
6-Aminonicotinamide
- CAS No.: 329-89-5
- Formula:C6H7N3O
- Molecular Weight:137.14
IUPAC Name: 6-aminonicotinamide
InChIKey: ZLWYEPMDOUQDBW-UHFFFAOYSA-N
SMILES: NC1=CC=C(C(N)=O)C=N1
Biological Activity: 6-Aminonicotinamide, a potent antimetabolite of nicotinamide, is competitive NADP+-dependent enzyme glucose-6-phosphate dehydrogenase (G6PD) inhibitor (Ki=0.46 μM). 6-Aminonicotinamide resultis ATP depletion and synergizes with DNA-crosslinking chemotherapy agents, such as Cisplatin (HY-17394), in killing cancer cells[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
6-Aminonicotinamide | 99.95% | 6-Aminonicotinamide, a potent antimetabolite of nicotinamide, is competitive NADP+-dependent enzyme glucose-6-phosphate dehydrogenase (G6PD) inhibitor (Ki=0.46 μM). 6-Aminonicotinamide resultis ATP depletion and synergizes with DNA-crosslinking chemotherapy agents, such as Cisplatin (HY-17394), in killing cancer cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
6-Aminonicotinamide (Standard) | ≥98% | 6-Aminonicotinamide, a potent antimetabolite of nicotinamide, is competitive NADP+-dependent enzyme glucose-6-phosphate dehydrogenase (G6PD) inhibitor (Ki=0.46 μM). 6-Aminonicotinamide resultis ATP depletion and synergizes with DNA-crosslinking chemotherapy agents, such as Cisplatin (HY-17394), in killing cancer cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Cheng J, et al. TRIM21 and PHLDA3 negatively regulate the crosstalk between the PI3K/AKT pathway and PPP metabolism. Nat Commun. 2020;11(1):1880. Published 2020 Apr 20. [Content Brief]
- [2]. Almugadam SH, et al. Influence of 6-aminonicotinamide (6AN) on Leishmania promastigotes evaluated by metabolomics: Beyond the pentose phosphate pathway. Chem Biol Interact. 2018;294:167-177. [Content Brief]
- [3]. Tsouko E, et al. Regulation of the pentose phosphate pathway by an androgen receptor-mTOR-mediated mechanism and its role in prostate cancer cell growth. Oncogenesis. 2014;3(5):e103. Published 2014 May 26. [Content Brief]
- [4]. Koutcher JA, et al. Effect of 6-aminonicotinamide on the pentose phosphate pathway: 31P NMR and tumor growth delay studies. Magn Reson Med. 1996;36(6):887-892. [Content Brief]
